Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?

00:49 EDT 22nd October 2014 | BioPortfolio

Summary of "Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?"

Androgen suppression therapy (AST) was first described in 1941 as a treatment of prostate cancer (PCa) and remains the mainstay of therapy in patients with hormone-naïve metastatic disease. It also is used in locally advanced or recurrent disease and in combination with radiation therapy in patients with higher-risk features. Several approaches to AST have been developed as a result of increased understanding of the pathways controlling testosterone production. Increased recognition of the side effects has resulted in strategies to minimize complications associated with AST. Attempts to reduce AST adverse effects include intermittent hormonal therapy and methods to reduce amount of intracellular androgens without reducing the circulating testosterone levels.

Affiliation

Department of Urology, Wilmington VA Medical Center, 1601 Kirkwood Highway, Wilmington, DE, 19805, USA.

Journal Details

This article was published in the following journal.

Name: Current urology reports
ISSN: 1534-6285
Pages:

Links

PubMed Articles [26760 Associated PubMed Articles listed on BioPortfolio]

Androgen receptor antagonists for prostate cancer therapy.

Androgen deprivation is the mainstay therapy for metastatic prostate cancer. Another way of suppressing androgen receptor signaling is via AR antagonists or antiandrogens. Despite being frequently pre...

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer.

Mechanisms mediating androgen receptor (AR) reactivation in prostate cancer (PCa) that progresses after castration (castration-resistant prostate cancer, CRPC) and subsequent treatment with abirateron...

Targeting the Androgen Receptor in Prostate Cancer - A Resilient Foe.

Personalizing the use of cancer therapeutics is a major focus of current biomedical research. The pioneering work of Huggins and colleagues more than 70 years ago foreshadowed the modern era of precis...

Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.

Androgen hormones and the androgen receptor (AR) pathway are the main targets of anti-hormonal therapies for prostate cancer. However, resistance inevitably develops to treatments aimed at the AR path...

(P085) Exploiting Androgen-Induced DNA Double-Strand Breaks: Optimal Sequencing of Androgen Suppression and Radiation for Superior Tumor Control in the Treatment of Prostate Cancer.

Clinical Trials [4584 Associated Clinical Trials listed on BioPortfolio]

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain...

To Lengthen the Duration of the Off-Treatment of Intermittent Androgen Suppression

The purpose of this research study is to determine if an investigational drug called Exisulind will extend the "off-treatment" period of patients receiving intermittent androgen suppressio...

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

BNIT-PR-001 is an open-label, multi-center, Phase I dosing evaluation trial of MVA-BN®-PRO in men with androgen-insensitive prostate cancer. Patients will have PSA recurrence after being ...

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression...

Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of and...

Medical and Biotech [MESH] Definitions

A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Prostate Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Advertisement

Searches Linking to this Article